This website will be unavailable from Thursday, May 30, 2024 at 6:00 p.m. through Monday, June 3, 2024 at 7:00 a.m. due to data center maintenance.
Amend CSHB 2811 (house committee printing) as follows:
(1) On page 4, strike lines 21-23 and substitute the following:
(1) be verbal;
(2) On page 6, between lines 1 and 2, insert the following:
(c) A regulatory agency described by Subsection (a) may develop written guidelines for written information to be provided to the patient about the risks and benefits of a controlled substance or dangerous drug used to treat the patient's acute pain. The guidelines may not authorize the practitioner to provide the written information under this subsection in lieu of discussing the information verbally with the patient as described by Subsection (b).